Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 5/2016

01-10-2016 | Co-infections and Comorbidity (S Naggie, Section Editor)

Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV

Authors: Bassem Matta, Tzu-Hao Lee, Keyur Patel

Published in: Current HIV/AIDS Reports | Issue 5/2016

Login to get access

Abstract

Patients with HIV have a proclivity to develop liver fibrosis, especially when associated with other conditions such as HCV, HBV, and NAFLD. Identifying HIV-infected patients with significant fibrosis or cirrhosis plays an important role in clinical and therapeutic decision-making. Liver biopsy is currently considered as the gold standard for fibrosis assessment but carries many shortcomings (cost, invasiveness, complications, false negative rate of 20 %). Multiple non-invasive methods of liver fibrosis assessment have been developed, but not all have been studied in HIV-infected individuals. Non-invasive liver fibrosis tools include both serologic-based testing scores (rely on direct and/or indirect markers) such as APRI, FIB4, FibroTest, FibroSpect II, HepaScore, or imaging-based methods such as vibration controlled liver elastography. There is validated data to support the use of non-invasive modalities of fibrosis assessment in HIV-HCV co-infected individuals for the exclusion of cirrhosis, but may be poorly reliable or not enough data exists for the assessment of other co-morbid disease processes.
Literature
1.
Puoti M et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev. 2002;4(1):27–35.PubMed
2.
Staples Jr CT, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis. 1999;29(1):150-–4.CrossRefPubMed
3.
Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected Person. Ann Intern Med. 2003;138(3):197–207.CrossRefPubMed
4.
Guaraldi G et al. Nonalcoholic fatty liver disease in hiv-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis. 2008;47(2):250–7.CrossRefPubMed
5.
Thio CL et al. HIV-1, hepatitis b virus, and risk of liver-related mortality in the multicenter cohort study (MACS). Lancet. 2002;360(9349):1921–6.CrossRefPubMed
6.
7.
Thein HH et al. Natural history of hepatitis c virus infection in HIV-infected individuals and the impact of hiv in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22(15):1979–91.CrossRefPubMed
8.
Konerman MA et al. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology. 2014;59(3):767–75.CrossRefPubMedPubMedCentral
9.
Macias J et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology. 2009;50(4):1056–63.CrossRefPubMed
10.
European Association for Study of, L. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199–236.CrossRef
11.
Zoulim F et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut. 2015;64(11):1824–33.CrossRefPubMed
12.
Do A et al. Drug authorization for sofosbuvir/ledipasvir (harvoni) for chronic HCV infection in a real-world cohort: a new barrier in the HCV care cascade. PLoS One. 2015;10(8):e0135645.CrossRefPubMedPubMedCentral
13.
Canary LA, Klevens RM, Holmberg SD. Limited access to new hepatitis C virus treatment under state medicaid programs. Ann Intern Med. 2015;163(3):226–8.CrossRefPubMed
14.
Panel AIHG. Hepatitis C guidance: AASLD-idsa recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932–54.CrossRef
15.
16.
Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142(6):1293–302. e4.CrossRefPubMed
17.
18.
Poniachik J et al. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc. 1996;43(6):568–71.CrossRefPubMed
19.
Afdhal NH. Diagnosing fibrosis in hepatitis C: Is the pendulum swinging from biopsy to blood tests? Hepatology. 2003;37(5):972–4.CrossRefPubMed
20.
Kelleher TB et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol. 2005;43(1):78–84.CrossRefPubMed
21.
Rossi E et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem. 2003;49(3):450–4.CrossRefPubMed
22.
Forns X et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36(4 Pt 1):986–92.CrossRefPubMed
23.
Lin ZH et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53(3):726–36.CrossRefPubMed
24.
Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology. 2007;46(3):912–21.CrossRefPubMed
25.
Sterling RK et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–25.CrossRefPubMed
26.
Christensen C et al. Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients. J Viral Hepat. 2006;13(10):652–8.CrossRefPubMed
27.
Adams LA et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51(10):1867–73.CrossRefPubMed
28.
Cales P et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005;42(6):1373–81.CrossRefPubMed
29.
Lichtinghagen R et al. The enhanced liver fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol. 2013;59(2):236–42.CrossRefPubMed
30.
Schmid P et al. Progression of liver fibrosis in HIV/hcv co-infection: a comparison between non-invasive assessment methods and liver biopsy. PLoS One. 2015;10(9):e0138838.CrossRefPubMedPubMedCentral
31.
Myers RP et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS. 2003;17(5):721–5.CrossRefPubMed
32.
Sulkowski MS et al. Elevated liver enzymes following initiation of antiretroviral therapy. JAMA. 2000;283(19):2526–7.CrossRefPubMed
33.
Macias J et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut. 2006;55(3):409–14.CrossRefPubMedPubMedCentral
34.
Loko MA et al. Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 aquitaine cohort. Am J Gastroenterol. 2008;103(8):1973–80.CrossRefPubMed
35.
Cacoub P et al. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study—ANRS HC02. J Hepatol. 2008;48(5):765–73.CrossRefPubMed
36.
Macias J et al. Use of simple noninvasive biomarkers to predict liver fibrosis in HIV/HCV coinfection in routine clinical practice. HIV Med. 2010;11(7):439–47.PubMed
37.
Cales P et al. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. J Hepatol. 2010;53(2):238–44.CrossRefPubMed
38.
Kliemann DA et al. Biochemical non-invasive assessment of liver fibrosis cannot replace biopsy in HIV-HCV coinfected patients. Ann Hepatol. 2015;15(1):27–32.CrossRef
39.
40.
Cole JL et al. Ineffective platelet production in thrombocytopenic human immunodeficiency virus-infected patients. Blood. 1998;91(9):3239–46.PubMed
41.
Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev. 2003;5(1):36–43.PubMed
42.
Bonacini M. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. Clin Infect Dis. 2004;38 Suppl 2:S104–8.CrossRefPubMed
43.
Rivero A, Mira JA, Pineda JA. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother. 2007;59(3):342–6.CrossRefPubMed
44.
Wilder J, Patel K. The clinical utility of FibroScan((R)) as a noninvasive diagnostic test for liver disease. Med Devices (Auckl). 2014;7:107–14.
45.
Lupsor M et al. Performance of a new elastographic method (arfi technology) compared to unidimensional transient elastography in the noninvasive assessment of chronic hepatitis C. Preliminary Results J Gastrointest Liver Dis. 2009;18(3):303–10.
46.
Takahashi H et al. Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study. Liver Int. 2010;30(4):538–45.CrossRefPubMed
47.
Ichikawa S et al. Comparison of the diagnostic accuracies of magnetic resonance elastography and transient elastography for hepatic fibrosis. Magn Reson Imaging. 2015;33(1):26–30.CrossRefPubMed
48.
European Association for Study of, L. and H. Asociacion Latinoamericana Para el Estudio del, EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237–64.CrossRef
49.
Castera L et al. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343–50.CrossRefPubMed
50.
de Ledinghen V et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr. 2006;41(2):175–9.CrossRefPubMed
51.
Vergara S et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 2007;45(8):969–74.CrossRefPubMed
52.
Kirk GD et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C Virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis. 2009;48(7):963–72.CrossRefPubMedPubMedCentral
53.
Sanchez-Conde M et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat. 2010;17(4):280–6.CrossRefPubMed
54.
Pineda JA et al. Liver stiffness as a predictor of esophageal varices requiring therapy in HIV/hepatitis C virus-coinfected patients with cirrhosis. J Acquir Immune Defic Syndr. 2009;51(4):445–9.CrossRefPubMed
55.
Castera L et al. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration. HIV Med. 2014;15(1):30–9.CrossRefPubMed
56.
Sellier P et al. Description of liver disease in a cohort of HIV/HBV coinfected patients. J Clin Virol. 2010;47(1):13–7.CrossRefPubMed
57.
Hjorth-Hansen H, Waage A, Borset M. Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells. Br J Haematol. 1999;106(1):28–34.CrossRefPubMed
58.
Clinical Practice Guidelines EASL-ALEH. Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237–64.CrossRef
59.
Bottero J et al. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. J Hepatol. 2009;50(6):1074–83.CrossRefPubMed
60.
Poynard T et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol. 2004;3(1):8.CrossRefPubMedPubMedCentral
61.
Sporea I et al. Liver stiffness measurements in patients with HBV vs HCV chronic hepatitis: a comparative study. World J Gastroenterol. 2010;16(38):4832–7.CrossRefPubMedPubMedCentral
62.
Cardoso AC et al. Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int. 2012;32(4):612–21.CrossRefPubMed
63.
Miailhes P et al. Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients. J Viral Hepat. 2011;18(1):61–9.CrossRefPubMed
64.
65.
Ingiliz P et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology. 2009;49(2):436–42.CrossRefPubMed
66.
67.
Grunfeld C. Insulin resistance in HIV infection: drugs, host responses, or restoration to health? Top HIV Med. 2008;16(2):89–93.PubMed
68.
Carr A et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14(3):F25–32.CrossRefPubMed
69.
Shah AG et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104–12.CrossRefPubMedPubMedCentral
70.
McPherson S et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59(9):1265–9.CrossRefPubMed
71.
Wong VW et al. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol. 2008;103(7):1682–8.PubMed
72.
Morse CG et al. Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-monoinfected adults with elevated aminotransferase levels on antiretroviral therapy. Clin Infect Dis. 2015;60(10):1569–78.PubMedPubMedCentral
73.
Wong VW et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2012;107(12):1862–71.CrossRefPubMed
74.
Wong VW et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51(2):454–62.CrossRefPubMed
75.
Yoneda M et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis. 2008;40(5):371–8.CrossRefPubMed
76.
Lupsor M et al. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. J Gastrointestin Liver Dis. 2010;19(1):53–60.PubMed
77.
Bureau C et al. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. Aliment Pharmacol Ther. 2008;27(12):1261–8.CrossRefPubMed
78.
Lemoine M et al. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis. Aliment Pharmacol Ther. 2008;28(9):1102–10.CrossRefPubMed
79.
Shi KQ et al. Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. Liver Int. 2013;33(1):62–71.CrossRefPubMed
80.
Vizzutti F et al. Liver stiffness measurement predicts severe portal hypertension in patients with hcv-related cirrhosis. Hepatology. 2007;45(5):1290–7.CrossRefPubMed
81.
Colecchia A et al. Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology. 2012;143(3):646–54.CrossRefPubMed
82.
Masuzaki R et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49(6):1954–61.CrossRefPubMed
83.
Jung KS et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011;53(3):885–94.CrossRefPubMed
84.
Robic MA et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol. 2011;55(5):1017–24.CrossRefPubMed
Metadata
Title
Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV
Authors
Bassem Matta
Tzu-Hao Lee
Keyur Patel
Publication date
01-10-2016
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 5/2016
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-016-0329-5

Other articles of this Issue 5/2016

Current HIV/AIDS Reports 5/2016 Go to the issue

Complications of Antiretroviral Therapy (G McComsey, Section Editor)

Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy

The Global Epidemic (SH Vermund, Section Editor)

Past and Future Performance: PEPFAR in the Landscape of Foreign Aid for Health

Central Nervous System and Cognition (SS Spudich, Section Editor)

Guidelines for Evaluation and Management of Cognitive Disorders in HIV-Positive Individuals

Complications of Antiretroviral Therapy (G McComsey, Section Editor)

Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence

The Global Epidemic (SH Vermund, Section Editor)

HIV Testing Services in Africa: Are They Sustainable?

Co-infections and Comorbidity (S Naggie, Section Editor)

HIV, Aging, and Viral Coinfections: Taking the Long View
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits